MedPath

Satureja hortensis effect on serum glucose, lipids, inflammatory factor and blood pressure in metabolic syndrome patients

Phase 3
Completed
Conditions
Metabolic Syndrome.
Metabolic disorder, unspecified
Registration Number
IRCT2014012616372N1
Lead Sponsor
Shiraz University of Medical Sciences, Vice Chancellor for Research Affairs
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Waist circumference men = 102cm or 40in and women = 88cm or 35in, Fasting blood glucose = 110 mg/dl, HDL-cholesterol for men < 40 mg/dl and for women < 50 mg/dl, Triglycerides = 150 mg/dl, Blood pressure = 130/85 mm Hg.
Exclusion criteria: hypothyroidism; alcoholism; smoking; auto immune disease; chronic pancreatitis; liver dysfunction; kidney disorder or nephritic syndrome; simultaneous subscription in other interventional study; any inflammatory disease or incidence of infection at start or during the study period; consumption of other drug such as aspirin, propranolol, NSAIDs, any form of steroids and any kind of blood glucose and lipid lowering agent; angioplasty or heart attack positive history; pregnancy and lactating.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Fasting Blood Glucose. Timepoint: Begining of study first day and at the end of study 70th day. Method of measurement: Laboratory kit, Pars Azmoon.;LDL-cholesterol. Timepoint: Begining of study first day and at the end of study 70th day. Method of measurement: Laboratory kit, Pars Azmoon.;High sensetive- C Reactive Protein. Timepoint: Begining of study first day and at the end of study 70th day. Method of measurement: Laboratory kit, Pars Azmoon.;Blood Pressure (systolic and diastolic). Timepoint: Begining of study first day and at the end of study 70th day. Method of measurement: Beurer Upper Arm Digital Blood Pressure Monitor.;HDL-cholesterol. Timepoint: Begining of study first day and at the end of study 70th day. Method of measurement: Laboratory kit, Pars Azmoon.;Triglyceride. Timepoint: Begining of study first day and at the end of study 70th dayBegining and end of study. Method of measurement: Laboratory kit, Pars Azmoon.
Secondary Outcome Measures
NameTimeMethod
Alanine Aminotransferase. Timepoint: Begining of study first day and at the end of study 70th day. Method of measurement: Laboratory kit, Pars Azmoon.;Aspartate Aminotransferase. Timepoint: Begining of study first day and at the end of study 70th day. Method of measurement: Laboratory kit, Pars Azmoon.;Complete Blood Count. Timepoint: Begining of study first day and at the end of study 70th day. Method of measurement: CBC counter machine, Sysmex.
© Copyright 2025. All Rights Reserved by MedPath